SPONSOR

Fudan University

Total Trials

Recruiting

Phases

Phase 2, Phase 3, Phase 1, Phase 2, Phase 1

Conditions studied: NSCLC Stage IV TNBC - Triple-Negative Breast Cancer Esophageal Squamous Cell Carcinoma Oligometastatic Disease Radiotherapy Colorectal Cancer Relapse High-Risk Localized Soft Tissue Sarcoma Differentiated Thyroid Cancer Cancer

Fudan University is a clinical research sponsor with 45 registered studies on ClinicalTrials.gov, of which 45 are actively recruiting participants. Research covers conditions including NSCLC Stage IV, TNBC - Triple-Negative Breast Cancer, Esophageal Squamous Cell Carcinoma, Oligometastatic Disease.

The trial portfolio spans Phase 2, Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Fudan University

How many clinical trials has Fudan University sponsored?

ClinicalMetric currently tracks 45 clinical trials sponsored by Fudan University, of which 45 are actively recruiting participants. These trials cover conditions including NSCLC Stage IV, TNBC - Triple-Negative Breast Cancer, Esophageal Squamous Cell Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Fudan University research focus on?

Fudan University clinical trials span NSCLC Stage IV, TNBC - Triple-Negative Breast Cancer, Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy, and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Fudan University clinical trial?

To participate in a Fudan University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fudan University trials with current recruitment status updated daily.

Fudan University

Frequently Asked Questions — Fudan University

Clinical Trials by Fudan University

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy

The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue

Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions

Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer

Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases

Lymph Node Pathologic Grading Strategy

Selective Neck Dissection Versus Modified Neck Dissection in PTC

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

Reverse Triple Negative Immune Resistant Breast Cancer

G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

ctDNA-guided Treatment Decision-making

Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery

Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )

Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)

Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

The Study on the Mechanism of Radiotherapy-elicited Immune Response

AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial

The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.

Precision Palliative Care for Patients With Advanced Esophageal Cancer